Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Oregon OTC-To-Rx Pseudoephedrine Bill Challenges FDA Authority - Lawyers

This article was originally published in The Tan Sheet

Executive Summary

An Oregon meth control bill making pseudoephedrine products available only by prescription encroaches on FDA's authority over the classification of drugs, according to some food & drug law experts

You may also be interested in...



Combat Meth Act Heads To Senate Floor Without Federal Preemption Clause

The Senate Judiciary Committee unanimously passed the Combat Meth Act of 2005 (S 103) July 28 after adopting an amendment that strikes the federal preemption provision from the bill

Oregon Pseudoephedrine Prescription Status Bill Heads To Senate

A bill that would require a prescription for purchase of products containing pseudoephedrine and other methamphetamine precursors passed the Oregon House of Representatives July 20

Supplement GMP Warning Letters Make Modest Debut In 2010

Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS098514

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel